Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis
- DOI
- 10.1111/iju.70699
- Published
- 2026-11
- Container
- International Journal of Urology
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1111/iju.70699,
title = {Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis},
author = {Makito Miyake},
year = {2026},
journal = {International Journal of Urology},
doi = {10.1111/iju.70699},
url = {https://doi.org/10.1111/iju.70699}
}RIS
TY - JOUR TI - Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis AU - Makito Miyake PY - 2026 JO - International Journal of Urology DO - 10.1111/iju.70699 UR - https://doi.org/10.1111/iju.70699 ER -
APA
Miyake, M. (2026). Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis. International Journal of Urology. https://doi.org/10.1111/iju.70699
Source records
- crossref · retrieved 2026-11-10T01:08:45.202Z